(+) Lazard Capital Markets Healthcare Conference (Repros) - Nov 15, 2012 - Anticipated initiation of P2 trial of low dose oral formulation for uterine fibroids and endometriosis by Q4 2012; Anticipated data from P2 trial in vaginal uterine fibroids in Q4 2012
Anticipated new P2 trial • Anticipated P2 data • Endometriosis • Uterine Leiomyoma
|